CreaGen offers CRO services to early-stage companies affected by coronavirus outbreak
The novel coronavirus (SARS-CoV-2) continues to disrupt overseas operations for biotech companies; CreaGen Inc., C2I Accelerator's CRO extension, offers chemistry resources and services for biotech firms.
Dr. Raj Rajur and the team at CreaGen Inc. have more than 16 years of experience in collaborating with more than 50 biotech and pharmaceutical companies and a number of Federal agencies. Their core expertise is in synthesis of new chemical entities, preclinical drug discovery research, scale-up synthesis and early stage process development.
If you interested in our services, please email email@example.com or call 978-764-7068 for additional information.
To read the full article, click here.
To visit CreaGen's website, click here.